WT1 Assay Portfolio Service

With unrivaled expertise and experiences in immune-oncology discovery and development, Creative Biolabs is confident in providing an integrated solution for WT1 assay services to best suit your program requirements.

Tumor Target WT1

WT-1, encoded by Wilms’ tumor gene 1 (WT1), is a 52-54 kD protein consisting of four zinc finger domains at the C terminus, and glutamine and proline-rich domain at the N terminus. WT1 plays an important role in cell growth, differentiation, apoptosis, organ development and maintenance.

In recent years, WT1 has been considered as a vital tumor-associated antigen, and is highly expressed in leukemias such as acute lymphoblastic leukemia (ALL) and acute myelocytic leukemia (AML), as well as solid tumors such as lung cancer, breast cancer, glioblastomas and thyroid cancer. Therefore, it has been defined as a promising prognostic tumor marker that has been widely explored in several tumors.

Fig.1 Positivity of WT1 overexpression in various cancers. (Sugiyama, 2010)

WT1 Targeted Therapeutics Strategies

With the in-depth study of tumor-associated antigen WT1, therapeutic strategies targeting WT1 are becoming increasingly promising. Some WT1 vaccine therapies, such as OCV-501 (Otsuka Pharmaceutical), TLP0-001 (Tella, Inc), are being developed and showed clinical effects in AML patients. Moreover, there are many approaches targeting WT1 which have been studied, including WT1 peptide-based vaccine immunotherapy, WT1 targeted TCRm-ADCs, bsAbs, CAR-T therapies. These approaches showed a specific anti-tumor effect in vitro and in the xenograft model, providing more potential for follow-up research.

Fig.2 WT1 peptide-based vaccine immunotherapy. (Creative Biolabs)

Our WT1 Assay Portfolio Services

Creative Biolabs has established, optimized several platforms, and provides high-quality WT1 assay portfolio services to help our clients meet their program requirements. We are committed to providing more comprehensive and accurate analytical results, covering the initial target validation to the later preclinical analysis to meet the requirements of scientific research.

For more details of our WT1 assay portfolio services, please don’t hesitate to contact us for more information.

References

1. Sugiyama, H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Japanese journal of clinical oncology. 2010, 40(5): 377-387.
2. Przespolewski, A.; et al. Advances in immunotherapy for acute myeloid leukemia. Future Oncology. 2018, 14(10): 963-978.

For Research Use Only | Not For Clinical Use